Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery
Author(s) -
Rajendra H. Mehta,
Jeffrey D. Leimberger,
Sean van Diepen,
James M. Meza,
Alice Wang,
Rachael Jankowich,
Robert W. Harrison,
Douglas W.P. Hay,
Stephen E. Fremes,
Andra I. Duncan,
Edward G. Soltesz,
John M. Luber,
Soon Park,
Michael Argenziano,
Edward Murphy,
Randy J. Marcel,
Dimitri Kalavrouziotis,
Dave Nagpal,
John Bozinovski,
Wolfgang Toller,
Matthias Heringlake,
Shaun G. Goodman,
Jerrold H. Levy,
Robert A. Harrington,
Kevin J. Anstrom,
John H. Alexander
Publication year - 2017
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1616218
Subject(s) - medicine , levosimendan , ejection fraction , placebo , cardiac surgery , clinical endpoint , myocardial infarction , perioperative , anesthesia , cardiopulmonary bypass , cardiology , population , inotrope , randomized controlled trial , surgery , heart failure , alternative medicine , environmental health , pathology
Levosimendan is an inotropic agent that has been shown in small studies to prevent or treat the low cardiac output syndrome after cardiac surgery.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom